

Merck just agreed to let seven companies make free generic versions of its experimental HIV prevention pill for low and middle-income countries.

The pharmaceutical giant isn't waiting for approval—it's planning ahead so millions can access the once-a-month pill as soon as it's ready.

Want to know more?